Estrogen replacement therapy and non-hormonal medication use among patients with uterine cancer

被引：0

作者：

Suzuki, Yukio ^{[1
]}

Chen, Ling ^{[1
]}

Ferris, Jennifer S. ^{[1
,2
]}

Clair, Caryn M. St. ^{[1
,3
,4
]}

Hou, June Y. ^{[1
,3
,4
]}

Khoury-Collado, Fady ^{[1
,3
,4
]}

Pua, Tarah ^{[1
,3
,4
]}

de Meritens, Alexandre Buckley ^{[1
,3
,4
]}

Accordino, Melissa ^{[1
,3
,4
]}

Hershman, Dawn L. ^{[1
,2
,3
,4
]}

Wright, Jason D. ^{[1
,3
,4
,5
]}

机构：

[1] Columbia Univ, Coll Phys & Surg, New York, NY USA

[2] Columbia Univ, Joseph L Mailman Sch Publ Hlth, New York, NY USA

[3] Herbert Irving Comprehens Canc Ctr, New York, NY USA

[4] New York Presbyterian Hosp, New York, NY USA

[5] Columbia Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, Coll Phys & Surg, 161 Ft Washington Ave,8th Floor, New York, NY 10032 USA

来源：

GYNECOLOGIC ONCOLOGY | 2024年 / 180卷

关键词：

Available online xxxx; Hormone replacement therapy; Menopause; Hot flash; Endometrial cancer; Uterine cancer; ENDOMETRIAL CANCER; POSITION STATEMENT; MENOPAUSE; SURVIVORS; SYMPTOMS;

D O I：

10.1016/j.ygyno.2023.11.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective. As the prognosis for endometrial cancer is excellent, management of the effects of estrogen deprivation has an important influence on quality of life. We examined the trends in the use of estrogen replacement therapy (ERT) and non-hormonal medications among patients with uterine cancer following surgery.Methods. The MarketScan Database was used to identify patients 18-49 years who underwent hysterectomy plus oophorectomy and those aged 50-75 years who underwent hysterectomy between 2008 and 2020. ERT and non-hormonal treatments of menopause were identified preoperatively and postoperatively. After propensity score balancing, difference-in-differences (DID) analyses were performed to compare the pre-andpostoperative changes in ERT and non-hormonal medication use between groups. The trends in postoperative use of ERT were assessed and tested using Cochran-Armitage trend tests.Results. A total of 19,700 patients with uterine cancer and 185,150 controls were identified. Overall, postoperative ERT use decreased for both age groups and for patients with and without uterine cancer. The DID in ERT use between those with uterine cancer and those with benign pathology after hysterectomy was -37.1% (95% CI, -40.5 to -33.6%) for patients 18-49 years of age and - 10.4% (95% CI, -10.9 to -9.9%) for those 50-75 years. The DID for non-hormonal medication use between those with uterine cancer and those with benign pathology after hysterectomy was 11.2% (95% CI, 7.8 to 14.7%) for younger patients and 3.4% (95% CI, 2.9 to 4.0%) for those 50-75 years. The postoperative new ERT use has been declining over time in patients with uterine cancer in those 18-49 years of age (P = .02) and those 50-75 years of age (P < .001).Conclusions. The use of ERT is uncommon and has declined over time in patients with uterine cancer. Conversely, non-hormonal medications are more commonly used among patients with uterine cancer.(c) 2023 Elsevier Inc. All rights reserved.

引用

页码：14 / 23

页数：10

共 29 条

[1] The 2012 Hormone Therapy Position Statement of The North American Menopause Society [J].